Tavanic by Sanofi Aventis during the 3rd Ask A Doc Dinner

1. TAVANIC
levofloxacin
1

2. Mode Of Action
Rapid bactericidal action:
inhibits DNA gyrase (resealing)
inhibits topoisomerase IV
(no separation of interlinked daughter DNA molecules)
2

3. Pharmacokinetics
Rapid, complete absorption after oral administration
100% bioavailable
T-max : 1 hour
IV and oral formulations are bioequivalent  switch /
sequential therapy
Minimal hepatic metabolism; 2 metabolites identified in
urine (<5% of total Levofloxacin)
Half life is 6 – 8 hours
once daily dosage
3

4. Indications
a) Upper respiratory tract infections –
sinusitis due to:
GRAM-POSITIVE GRAM-NEGATIVE
*
M. catarrhalis **
S. pneumoniae
H. influenzae ***
S. aureus ***
H. parainfluenzae
* -lactamase producers
** intraphagocytic
6

5. Indications (Cont…)
b) Lower respiratory tract infections:
acute exacerbation of chronic bronchitis (AECB) due to:
GRAM-POSITIVE GRAM-NEGATIVE
*
M. catarrhalis **
H. influenzae ***
S. pneumoniae
H. parainfluenzae
S. aureus ***
K. pneumoniae*
E. coli*
* -lactamase producers
** intraphagocytic
7

6. Indications (Cont…)
c) Lower respiratory tract infections (cont):
Community acquired pneumonia (CAP) due to:
GRAM- GRAM- ATYPICAL
POSITIVE NEGATIVE BACTERIA
S. pneumoniae M. catarrhalis*** M. pneumoniae ***
* *
S. aureus ** H. influenzae ** C. pneumoniae ***
H. parainfluenzae L. pneumophila ***
K. pneumoniae*
E. coli*
* -lactamase producers
** intraphagocytic
*** intracellular
8

7. Indications (Cont…)
e) Skin and soft tissue infections:
uncomplicated infections such as abscess, cellulitis, carbuncles,
impetigo due to:
GRAM-POSITIVE GRAM-NEGATIVE
Acinitobacter
Enterobacter
S. aureus **
P. mirabilis
S. pyogenes
P. aeruginosa
S. faecalis
E. coli*
K. pneumoniae*
* -lactamase producers
** intra-phagocytic
10

8. Indications (Cont…)
f) Complicated skin and soft tissue infections
such as diabetic foot ulcers, pressure sores, traumatic and post-
surgical wound infections due to:
GRAM-POSITIVE GRAM-NEGATIVE
P. mirabilis
S. aureus* E. coli*
S. pyogenes K. pneumoniae*
S. faecalis Enterobacter
K. oxytoca
* -lactamase producers
** intra-phagocytic
11

9. Dosage
500mg once daily, which enhances patient
compliance.
Bioequivalent Oral or IV , allows for switch
therapy.
Dosage and duration depends on the type and
severity of infection.
Continue for a further 48 - 72 hours after patient
is afebrile or evidence of bacteriological
eradication.
13

10. 14

11. 15